COVID-19 vaccine effectiveness studies in Nigeria: Quo vadis?
Oluwatosin Wuraola
Akande
;
Ehimario Uche
Igumbor
;
Kelly Osezele
Elimian
;
Cornelius Ehizokhai
Ohonsi
;
Lilian
Nwozor
;
Okanke
Oden
;
Emmanuel Nsa
Ekpenyong
;
Nnaemeka
Ndodo
;
Ifeanyi F
Ike
;
Magdalene
Egede
;
+6 more...
William
Nwachukwu
;
Amedu M
Onoja
;
Jenson Gawain
Fofah
;
Reuben Ishiaku
Azi
;
Chinwe L
Ochu
;
Ifedayo M
Adetifa
;
(2022)
COVID-19 vaccine effectiveness studies in Nigeria: Quo vadis?
Journal of global health, 12.
03055-.
ISSN 2047-2978
DOI: 10.7189/jogh.12.03055
;
(2022)
COVID-19 vaccine effectiveness studies in Nigeria: Quo vadis?
Journal of global health, 12.
03055-.
ISSN 2047-2978
DOI: 10.7189/jogh.12.03055
The “lickety-split” development of COVID-19 vaccines 326 days from when the SARS-COV-2 virus was first sequenced is indeed one of the public health successes of the 21st century. Particularly because an 18-month target was initially considered reasonable, and having achieved this success, a “moonshot” goal to ensure that a vaccine is available within 100 days after the next pandemic pathogen is recognized has been set [1].
-
picture_as_pdf - Akande_etal_2022_COVID-19-vaccine-effectiveness-studies.pdf
-
subject - Published Version
-
- Available under Creative Commons: Attribution 4.0
Downloads